Lipid-Based DNA Therapeutics: Hallmarks of Non-Viral Gene Delivery
Source abstract
Abstract
Gene therapy is a promising strategy for the treatment of monogenic disorders. Non-viral gene delivery systems including lipid-based DNA therapeutics offer the opportunity to deliver an encoding gene sequence specifically to the target tissue and thus enable the expression of therapeutic proteins in diseased cells. Currently, available gene delivery approaches based on DNA are inefficient and require improvements to achieve clinical utility. In this Review, we discuss state-of-the-art lipid-based DNA delivery systems that have been investigated in a preclinical setting. We emphasize factors influencing the delivery and subsequent gene expression in vitro, ex vivo, and in vivo. In addition, we cover aspects of nanoparticle engineering and optimization for DNA therapeutics. Finally, we highlight achievements of lipid-based DNA therapies in clinical trials.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Advanced biosensing and bioanalysis techniques · Virus-based gene therapy research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Division of Pharmaceutical Technology, Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056 Basel, Switzerland
Department of Biochemistry and Molecular Biology, University of British Columbia, 2350 Health Sciences Mall, Vancouver, British Columbia V6T 1Z3, Canada
Funding
Freiwillige Akademische Gesellschaft · Novartis · Schweizerischer Nationalfonds zur F?rderung der Wissenschaftlichen Forschung
References (100+)
Show source-provided references
1. 10.1126/science.849353010.1126/science.8493530 ↗
2. 10.1021/acs.nanolett.8b0043210.1021/acs.nanolett.8b00432 ↗
3. Gene Therapy Clinical Trials Worldwide Home Page. http://www.abedia.com/wiley/phases.php (accessed February 5, 2019).
4. 10.1038/sj.gt.330192310.1038/sj.gt.3301923 ↗
5. 10.1016/j.jconrel.2014.12.03010.1016/j.jconrel.2014.12.030 ↗
6. 10.1038/nrd177510.1038/nrd1775 ↗
7. 10.1039/C1CS15240H10.1039/C1CS15240H ↗
8. 10.1016/S0169-409X(00)00124-110.1016/S0169-409X(00)00124-1 ↗
9. 10.1038/nmat376510.1038/nmat3765 ↗
10. 10.1016/j.jconrel.2015.02.00310.1016/j.jconrel.2015.02.003 ↗
11. 10.1016/j.jhep.2013.05.04510.1016/j.jhep.2013.05.045 ↗
12. FDA News Release. FDA approves first-of-its kind targeted RNA-based therapy to treat a rare disease. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm616518.htm (accessed February 5, 2019).
13. 10.1016/j.jconrel.2011.11.01410.1016/j.jconrel.2011.11.014 ↗
14. 10.1038/sj.gt.330276110.1038/sj.gt.3302761 ↗
15. 10.1021/acsami.5b0168410.1021/acsami.5b01684 ↗
16. 10.1021/acs.nanolett.5b0249710.1021/acs.nanolett.5b02497 ↗
17. 10.1016/j.nano.2016.12.01410.1016/j.nano.2016.12.014 ↗
18. 10.1016/j.addr.2007.03.00510.1016/j.addr.2007.03.005 ↗
19. 10.1038/nrd274210.1038/nrd2742 ↗
20. 10.1038/nrg376310.1038/nrg3763 ↗
21. 10.1016/j.ymthe.2017.03.01310.1016/j.ymthe.2017.03.013 ↗
22. 10.1038/natrevmats.2017.5610.1038/natrevmats.2017.56 ↗
23. 10.4103/2277-9175.9815210.4103/2277-9175.98152 ↗
24. 10.7150/thno.691410.7150/thno.6914 ↗
25. 10.1038/ncb0309-22810.1038/ncb0309-228 ↗
26. 10.1038/nrd.2016.23810.1038/nrd.2016.238 ↗
27. 10.1016/j.cell.2014.05.01010.1016/j.cell.2014.05.010 ↗
28. 10.1126/science.125809610.1126/science.1258096 ↗
29. 10.1016/j.jconrel.2017.09.01210.1016/j.jconrel.2017.09.012 ↗
30. 10.1016/j.drudis.2018.01.01410.1016/j.drudis.2018.01.014 ↗
31. 10.1073/pnas.152024411310.1073/pnas.1520244113 ↗
32. 10.18632/oncotarget.1992910.18632/oncotarget.19929 ↗
33. 10.1038/mt.2013.12410.1038/mt.2013.124 ↗
34. 10.1016/j.bmcl.2016.04.00710.1016/j.bmcl.2016.04.007 ↗
35. 10.1002/jgm.293010.1002/jgm.2930 ↗
36. 10.1248/bpb.32.70610.1248/bpb.32.706 ↗
37. 10.1073/pnas.48.12.202610.1073/pnas.48.12.2026 ↗
38. Szybalska E. H. · CC/LIFE SCI. · 1991 · 11
39. Szybalska E. H. · Proc. Natl. Acad. Sci. U.S.A. · 1962 · 48 · 202610.1073/pnas.48.12.2026 ↗
40. 10.1016/0042-6822(65)90126-110.1016/0042-6822(65)90126-1 ↗
41. 10.1016/0042-6822(73)90341-310.1016/0042-6822(73)90341-3 ↗
42. 10.1089/hum.1994.5.4-46910.1089/hum.1994.5.4-469 ↗
43. 10.1073/pnas.75.3.136110.1073/pnas.75.3.1361 ↗
44. 10.1073/pnas.76.7.334810.1073/pnas.76.7.3348 ↗
45. 10.1093/nar/6.12.377310.1093/nar/6.12.3773 ↗
46. Fraley R. · J. Biol. Chem. · 1980 · 255 · 1043110.1016/S0021-9258(19)70482-7 ↗
47. 10.1126/science.705356710.1126/science.7053567 ↗
48. 10.1073/pnas.80.4.106810.1073/pnas.80.4.1068 ↗
49. 10.1073/pnas.84.21.741310.1073/pnas.84.21.7413 ↗
50. 10.1016/0006-291X(91)91366-K10.1016/0006-291X(91)91366-K ↗
51. 10.1083/jcb.118.5.100310.1083/jcb.118.5.1003 ↗
52. 10.1089/hum.1996.7.14-170110.1089/hum.1996.7.14-1701 ↗
53. 10.1146/annurev.biophys.29.1.2710.1146/annurev.biophys.29.1.27 ↗
54. Elouahabi, A.; Thiry, M.; Pector, V.; Ruysschaert, J.M.; Vandenbranden, M. Calorimetry of Cationic Liposome–DNA Complex and Intracellular Visualization of the Complexes; Enzymology, B.M. in, Ed.; Liposomes, Part C; Academic Press: Boca Raton, FL, 2003; Vol. 373, pp 312–332.10.1016/S0076-6879(03)73020-1 ↗
55. 10.1016/j.ymthe.2004.12.00610.1016/j.ymthe.2004.12.006 ↗
56. 10.1016/j.jconrel.2006.04.01410.1016/j.jconrel.2006.04.014 ↗
57. 10.1021/bc800403910.1021/bc8004039 ↗
58. Zugates, G. T. Synthesis and Chemical Modification of Degradable Polymers to Enhance Gene Delivery. Thesis, Massachusetts Institute of Technology, 2006. http://hdl.handle.net/1721.1/38970 (accessed February 5, 2019).
59. 10.1038/sj.gt.330052910.1038/sj.gt.3300529 ↗
60. 10.1089/nat.2018.072110.1089/nat.2018.0721 ↗
61. 10.1016/B978-0-12-800148-6.00002-X10.1016/B978-0-12-800148-6.00002-X ↗
62. 10.1016/j.addr.2015.02.00710.1016/j.addr.2015.02.007 ↗
63. 10.1021/bi960201910.1021/bi9602019 ↗
64. 10.1021/bc300381s10.1021/bc300381s ↗
65. Felgner J. H. · J. Biol. Chem. · 1994 · 28 · 255010.1016/S0021-9258(17)41980-6 ↗
66. 10.1016/j.jconrel.2012.04.00210.1016/j.jconrel.2012.04.002 ↗
67. 10.1016/j.biomaterials.2008.04.03610.1016/j.biomaterials.2008.04.036 ↗
68. Semple S. C. · 2000 · 313 · 322
69. 10.1016/j.jconrel.2005.06.01410.1016/j.jconrel.2005.06.014 ↗
70. 10.1038/nbt.160210.1038/nbt.1602 ↗
71. 10.1002/anie.20120326310.1002/anie.201203263 ↗
72. 10.1038/nbt140210.1038/nbt1402 ↗
73. 10.1073/pnas.091060310610.1073/pnas.0910603106 ↗
74. 10.1038/ncomms527710.1038/ncomms5277 ↗
75. 10.1038/mt.2009.14710.1038/mt.2009.147 ↗
76. 10.1021/bc200572w10.1021/bc200572w ↗
77. 10.1016/j.ymthe.2018.03.01010.1016/j.ymthe.2018.03.010 ↗
78. Acuitas Non-Confidential Presentation. https://acuitastx.com/wp-content/uploads/2018/09/Acuitas-non-confidential-presentation-2017.pdf (accessed February 5, 2019).
79. 10.1002/adma.20150288810.1002/adma.201502888 ↗
80. 10.1021/bc400158w10.1021/bc400158w ↗
81. 10.1021/acsami.7b1598210.1021/acsami.7b15982 ↗
82. 10.1021/jacs.5b0342910.1021/jacs.5b03429 ↗
83. 10.1002/smll.20180509710.1002/smll.201805097 ↗
84. 10.1021/acscombsci.5b0011710.1021/acscombsci.5b00117 ↗
85. 10.1016/j.jconrel.2005.08.01210.1016/j.jconrel.2005.08.012 ↗
86. 10.1016/0005-2736(95)80016-910.1016/0005-2736(95)80016-9 ↗
87. 10.1016/j.addr.2016.01.02210.1016/j.addr.2016.01.022 ↗
88. 10.1529/biophysj.106.08376610.1529/biophysj.106.083766 ↗
89. 10.1073/pnas.080995910610.1073/pnas.0809959106 ↗
90. 10.1016/j.bbamem.2004.03.00410.1016/j.bbamem.2004.03.004 ↗
91. 10.1016/S0014-5793(96)01397-X10.1016/S0014-5793(96)01397-X ↗
92. 10.1038/sj.gt.330068310.1038/sj.gt.3300683 ↗
93. 10.1038/mt.2009.3610.1038/mt.2009.36 ↗
94. 10.1016/j.biomaterials.2015.11.05610.1016/j.biomaterials.2015.11.056 ↗
95. 10.1002/(SICI)1520-6017(200005)89:5<652::AID-JPS11>3.0.CO;2-H10.1002/(SICI)1520-6017(200005)89:5<652::AID-JPS11>3.0.CO;2-H ↗
96. 10.1016/S0005-2736(01)00399-610.1016/S0005-2736(01)00399-6 ↗
97. 10.1038/mt.2010.8510.1038/mt.2010.85 ↗
98. 10.1016/j.addr.2013.08.01210.1016/j.addr.2013.08.012 ↗
99. 10.1093/nar/27.19.379210.1093/nar/27.19.3792 ↗
100. 10.1517/14712598.2015.99654410.1517/14712598.2015.996544 ↗